Cigna forecast annual profit below Wall Street expectations on Thursday and missed estimates for the fourth quarter, as ...
Cantor Fitzgerald lowered the firm’s price target on Cigna (CI) to $350 from $400 and keeps an Overweight rating on the shares. Cantor is ...
Cigna blamed lower-than-expected fourth-quarter returns on its stop-loss insurance business that insures employers from ...
Cigna Group plans to make changes to help lower out-of-pocket cost of prescription drugs, the company said on Wednesday, as ...
Oppenheimer lowered the firm’s price target on Cigna (CI) to $375 from $400 and keeps an Outperform rating on the shares. The firm notes ...
Cigna Group CEO David Cordani said the company will make investments this year to improve patient and provider experiences ...
23hon MSN
Shares of Cigna ( CI -8.00%) were dropping Thursday. The stock was down 8.4% as of 1:20 p.m. ET but had lost as much as 11.3% ...
Cigna Group plans to limit patients’ out-of-pocket expenses for medications as the insurer faces pressure from Washington ...
Cigna Group shares fell sharply after the health insurer reported fourth-quarter profit that was dragged down by medical ...
Cigna (CI) stock falls as the managed care company's Q4 2024 earnings miss the consensus due to an unexpected rise in medical ...
Cigna executives kicked off Thursday’s earnings call by responding to pharmacy benefit manager critics with a number of reforms.
The villains were injectable specialty drugs like Keytruda and inpatient surgical procedures for seriously ill patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback